A vaccine prepares the immune system to recognize a particular pathogen or pathogen-associated antigen before a person encounters the disease naturally.

Vaccines have been developed against diseases caused by both viruses and bacteria. Modern biotechnology has expanded the ways vaccines can be designed and manufactured.

Instead of always growing an entire pathogen, scientists may use:

• purified components of a pathogen
• proteins produced using genetically engineered cells
• harmless viral vectors carrying genetic instructions
• messenger RNA (mRNA)
• other nucleic-acid technologies

The goal remains the same:

Train the immune system to respond rapidly and effectively if the real pathogen is encountered later.

---

Pathogens and Disease

A pathogen is a disease-causing biological agent.

Major groups include:

• viruses
• bacteria
• fungi
• protozoa

When a pathogen enters the body, it may reproduce and interfere with normal cell or tissue function.

The immune system attempts to identify and eliminate the pathogen.

Vaccination gives the adaptive immune system an opportunity to develop a targeted response without requiring the person to experience the full disease first.

---

Antigens

An antigen is a molecule or molecular structure that can be recognized by components of the immune system.

Pathogens contain many potential antigens.

For example, proteins on the surface of a virus can act as antigens.

A vaccine presents selected antigens—or instructions for making them—to the immune system.

This can stimulate an adaptive immune response.

---

The Immune Response

The immune system has several interacting components.

Two important types of lymphocytes are:

B Cells

B cells can differentiate into cells that produce antibodies.

Antibodies can bind specifically to particular molecular targets.

T Cells

Different types of T cells have different functions.

Some coordinate immune responses, while others can recognize and destroy infected cells.

Vaccination can stimulate both antibody-mediated and cellular immune responses, depending on the vaccine.

---

Antibodies

Antibodies are proteins produced by specialized B cells.

They have binding regions that recognize particular molecular structures.

Antibody binding can help the immune system by:

• blocking pathogens from entering cells
• neutralizing toxins
• marking material for removal
• helping other immune mechanisms recognize a target

Different antibodies recognize different molecular structures.

---

Immune Memory

One of the most important features of vaccination is the formation and persistence of immune memory.

After an initial immune response, populations of memory B cells and T cells may remain.

If the same pathogen or antigen is encountered later:

recognition occurs more rapidly

↓

immune cells respond

↓

antibodies and other immune responses develop faster

↓

the pathogen may be controlled before severe disease develops

---

Primary and Secondary Immune Responses

The primary immune response occurs after first exposure to an antigen.

It generally takes time to develop.

After memory has formed, later exposure can produce a secondary immune response.

The secondary response is often:

• faster
• stronger
• more effective

This is the biological basis of vaccination.

A vaccine provides a controlled first exposure to antigenic information so the immune system is better prepared for later encounters.

---

How Vaccines Prevent Disease

A simplified pathway is:

vaccination

↓

antigen or genetic instructions presented

↓

immune system responds

↓

memory cells develop

↓

later exposure to pathogen

↓

faster immune response

↓

reduced likelihood of infection or severe disease, depending on the vaccine

Vaccines do not create an impenetrable physical barrier around a person.

Instead, they prepare the immune system.

---

Vaccination Does Not Always Prevent Infection

An important distinction is:

infection ≠ disease ≠ severe disease

Some vaccines are very effective at preventing infection.

Others are particularly valuable because they reduce:

• symptoms
• severe disease
• complications
• hospitalization
• death

Protection can also vary with:

• the vaccine
• pathogen variants or strains
• age
• immune status
• time since vaccination

Therefore, vaccine effectiveness should be described in relation to a specific outcome.

---

Traditional Vaccine Technologies

Several vaccine technologies were developed long before modern genetic engineering.

Major approaches include:

• live attenuated vaccines
• inactivated vaccines
• toxoid vaccines

These technologies remain important today.

---

Live Attenuated Vaccines

A live attenuated vaccine contains a weakened form of a pathogen.

The pathogen can produce a limited infection-like stimulus but has been altered or selected so that it does not normally cause the full disease in healthy recipients.

Examples include vaccines against:

• measles
• mumps
• rubella
• chickenpox

Advantages

They can produce strong, long-lasting immune responses.

Limitations

They may not be appropriate for some people with severely weakened immune systems and often require careful storage.

---

Inactivated Vaccines

An inactivated vaccine contains pathogens that have been killed or otherwise rendered unable to replicate.

Examples include some vaccines against:

• influenza
• polio
• hepatitis A
• rabies

Because the pathogen cannot reproduce, it cannot cause infection in the way the original pathogen can.

However, the immune response may sometimes require:

• multiple doses
• booster doses
• adjuvants

---

Toxoid Vaccines

Some bacteria cause disease largely through toxins they produce.

A toxoid vaccine uses an inactivated form of a bacterial toxin.

Examples include vaccines against:

• tetanus
• diphtheria

The immune system learns to recognize the toxin.

If exposure occurs later, antibodies can help neutralize it.

---

Subunit Vaccines

A subunit vaccine contains selected components of a pathogen rather than the entire pathogen.

These components may include:

• proteins
• polysaccharides
• combinations of these molecules

Only selected antigens are presented to the immune system.

Modern biotechnology has made it possible to manufacture some vaccine antigens using genetically engineered cells.

---

Recombinant Vaccines

One important biotechnology approach is recombinant protein production.

Scientists identify genetic information encoding a useful pathogen antigen.

The basic process is:

antigen gene identified

↓

genetic information placed into suitable production cells

↓

cells express the gene

↓

antigen produced

↓

antigen purified

↓

antigen formulated into vaccine

This is similar to the biotechnology used to produce recombinant insulin.

---

Hepatitis B: A Classic Example

The hepatitis B vaccine is a well-known example of recombinant vaccine technology.

Genetic information encoding a hepatitis B surface antigen can be introduced into yeast cells.

The yeast produces the viral antigen.

The antigen is then:

• collected
• purified
• formulated

into a vaccine.

The vaccine therefore does not require the person to be infected with hepatitis B virus.

---

Virus-Like Particles

Some vaccines use virus-like particles (VLPs).

VLPs resemble the external structure of a virus but lack the complete viral genetic material required for normal viral replication.

Because their surfaces resemble the virus, they can present antigens effectively to the immune system.

Some HPV vaccines use virus-like particles.

---

Viral-Vector Vaccines

Another biotechnology approach uses a viral vector.

A vector is a carrier.

Scientists modify a virus so that it carries genetic information encoding an antigen from another pathogen.

The vector delivers this genetic information into cells.

The cells then produce the antigen.

The immune system recognizes the antigen and develops a response.

A simplified pathway is:

engineered vector

↓

enters cells

↓

antigen gene expressed

↓

antigen produced

↓

immune response develops

---

mRNA Vaccines

Messenger RNA vaccines use a different strategy.

Instead of manufacturing the antigen first and injecting that antigen, the vaccine provides cells with temporary mRNA instructions for producing an antigen.

The cell's ribosomes translate the mRNA.

The process can be simplified as:

mRNA enters cell

↓

ribosome reads mRNA

↓

antigen produced temporarily

↓

immune system recognizes antigen

↓

adaptive immune response develops

↓

immune memory can form

---

What Happens to the mRNA?

The mRNA does not need to remain permanently in the cell.

Cells naturally contain enzymes that break down mRNA.

After the vaccine mRNA has been used:

mRNA → degraded

The antigen itself is also eventually broken down.

What can remain longer is the immune memory generated by the response.

---

mRNA and DNA

A common misconception is that vaccine mRNA needs to enter the nucleus and become part of a person's DNA.

For mRNA vaccines:

• the mRNA functions mainly in the cytoplasm
• ribosomes translate it into protein
• the vaccine mRNA is eventually degraded

It does not need to alter the cell's DNA in order to work.

---

Lipid Nanoparticles

RNA is fragile and does not easily enter cells on its own.

Some mRNA vaccines therefore package the mRNA inside lipid nanoparticles.

These tiny lipid-based structures:

• protect the mRNA
• help deliver it into cells
• allow the mRNA to reach the cytoplasm

This is an example of biotechnology combining:

molecular biology + chemistry + nanotechnology + medicine

---

DNA Vaccines

DNA vaccines provide DNA containing genetic instructions for an antigen.

Cells then use that information to produce the antigen.

The general idea is:

DNA instructions → RNA → antigen protein → immune response

DNA vaccines have been developed and used in some contexts, including veterinary medicine and some human vaccination programs.

---

Comparing Vaccine Technologies

There is no single vaccine technology that is ideal for every disease.

Scientists choose platforms according to the pathogen, desired immune response, safety considerations, manufacturing requirements, and available evidence.

---

Biotechnology and Vaccine Discovery

Biotechnology affects much more than vaccine manufacturing.

Scientists can use technologies such as genome sequencing to determine the genetic sequence of a pathogen.

Researchers can then investigate genes that encode potential antigens.

Modern vaccine research may involve:

• DNA sequencing
• genome analysis
• protein analysis
• structural biology
• cell culture
• recombinant DNA
• computational modelling
• immunological testing

This can make vaccine development more targeted.

---

From Pathogen to Vaccine Candidate

A simplified modern development pathway might look like:

identify pathogen

↓

sequence and study genome

↓

identify possible antigens

↓

design vaccine candidates

↓

laboratory testing

↓

preclinical testing

↓

clinical trials

↓

regulatory review

↓

manufacturing

↓

continued safety monitoring

Finding an antigen is therefore only the beginning.

---

Clinical Trials

Vaccines must be tested before widespread use.

Clinical development generally proceeds through stages.

Early Trials

Researchers investigate:

• safety
• dose
• immune response

Larger Trials

Researchers investigate:

• effectiveness
• less common adverse effects
• performance in larger populations

Regulators then evaluate the total evidence.

After authorization or approval, safety monitoring continues as the vaccine is used more widely.

---

Why Large Studies Matter

Suppose an unwanted effect occurs naturally in approximately:

1 person in 50,000

A trial involving only 100 people would be very unlikely to detect it.

Larger studies and post-authorization monitoring are therefore important for identifying uncommon events.

This illustrates an important principle:

Absence of an event in a small study does not prove that its risk is zero.

Science uses increasingly large datasets to estimate both benefits and risks.

---

Vaccine Effectiveness

Imagine a study with two equally sized groups.

In the unvaccinated group:

100 people develop the disease.

In the vaccinated group:

20 people develop the disease.

The relative reduction in disease incidence is:

(100 − 20) ÷ 100 × 100

= 80%

Under this simplified example, the vaccine shows an 80% relative reduction in the measured outcome.

However, real vaccine-effectiveness calculations require carefully designed studies and appropriate comparison of rates.

---

Effectiveness Is Outcome-Specific

A statement such as:

"This vaccine is 90% effective."

is incomplete unless we know:

90% effective against what?

Possible outcomes include:

• infection
• symptomatic disease
• severe disease
• hospitalization
• death

A vaccine may have different effectiveness values for different outcomes.

---

Biotechnology During Disease Outbreaks

Disease outbreaks create an urgent need to identify and understand pathogens.

Biotechnology can contribute through:

• diagnostic testing
• genome sequencing
• surveillance
• vaccine development
• therapeutic research
• monitoring pathogen evolution

---

Identifying a New Pathogen

When an unusual outbreak occurs, scientists can collect samples and analyze genetic material.

Genome sequencing can help researchers:

• identify the pathogen
• compare samples
• track genetic changes
• identify possible antigens
• develop diagnostic tests

Genetic information can be shared internationally so researchers in different locations can work on the same problem.

---

Rapid Vaccine Design

Some modern vaccine platforms can be redesigned relatively quickly once scientists know the genetic sequence of an important antigen.

For example, an mRNA platform can be adapted by changing the sequence encoded by the mRNA.

The underlying manufacturing platform may remain broadly similar.

This can shorten parts of the design process.

However:

Fast design does not mean safety and effectiveness testing should be skipped.

Candidate vaccines still require appropriate testing, quality control, and regulatory evaluation.

---

Genomic Surveillance

Pathogens can evolve.

Viruses in particular can accumulate genetic changes as they reproduce.

Scientists can sequence samples collected over time.

This allows researchers to:

• identify variants
• investigate transmission patterns
• monitor important mutations
• determine whether diagnostic tests or vaccines may need reassessment

This process is called genomic surveillance.

---

Vaccines and Population-Level Protection

Vaccination can protect the vaccinated individual, but it may also influence disease transmission at the population level.

If a vaccine reduces infection or infectiousness, widespread vaccination can reduce opportunities for a pathogen to spread.

This can indirectly protect some people who remain susceptible.

This concept contributes to population immunity.

However, the amount of vaccination needed depends on factors such as:

• how contagious the pathogen is
• how effective the vaccine is at reducing transmission
• how long protection lasts
• population mixing patterns

There is no single population-immunity percentage that applies to every disease.

---

Why Population Protection Matters

Some people may not receive particular vaccines because of:

• age
• specific medical circumstances
• severe allergies to particular components
• some forms of immune suppression

Reducing pathogen transmission can therefore provide benefits beyond the individual receiving a vaccine.

This makes vaccination both an individual health intervention and, for many infectious diseases, a public-health strategy.

---

Vaccines and Disease Control

Vaccination has contributed to major reductions in many infectious diseases.

Perhaps the most striking example is smallpox.

A coordinated global vaccination and surveillance campaign eventually eliminated naturally occurring smallpox transmission.

The World Health Organization declared smallpox eradicated in 1980.

It remains one of the clearest examples of vaccination's potential impact on global public health.

---

Disease Elimination vs Eradication

These terms are different.

Elimination

Transmission of a disease is reduced to zero within a particular geographic region, but continued prevention measures may still be needed.

Eradication

Transmission is reduced to zero worldwide.

Smallpox is an example of eradication.

Eradication is extremely difficult and depends on biological, technological, political, logistical, and social factors.

---

Vaccines and Antibiotics

Vaccines and antibiotics have very different roles.

Vaccines

Usually aim to prevent disease before infection or severe illness occurs by preparing the immune system.

Antibiotics

Treat susceptible bacterial infections.

Antibiotics do not treat viral infections such as influenza.

Vaccination against bacterial diseases can also sometimes reduce the need for antibiotics, potentially helping efforts to limit antimicrobial resistance.

---

Vaccine Safety

No medical intervention can be guaranteed to have zero risk.

Vaccines can cause side effects.

Common effects may include:

• soreness at the injection site
• fatigue
• mild fever
• headache

Serious adverse reactions can occur but are generally much less common and vary by vaccine.

The relevant scientific question is therefore not:

"Is there absolutely zero risk?"

Instead, researchers evaluate:

What are the observed benefits and risks for the specific vaccine and population?

---

Monitoring Vaccine Safety

Safety monitoring does not end when a vaccine is introduced.

Scientists and health authorities continue to collect information.

This is called pharmacovigilance.

Researchers may compare:

• observed health events
• expected background rates
• vaccinated populations
• appropriate comparison groups

This helps determine whether an event that happened after vaccination was actually associated with the vaccine or merely occurred at the same time.

---

Correlation Is Not Automatically Causation

Suppose a person develops a headache one week after vaccination.

We can correctly say:

the headache occurred after vaccination.

But this alone does not prove:

the vaccination caused the headache.

Scientists investigate possible causal relationships using:

• comparison groups
• biological evidence
• timing
• repeated observations
• statistical analysis
• large datasets

This principle applies throughout medical science.

---

Evaluating Vaccine Impact

The impact of a vaccination program can be evaluated using several measures.

Scientists might examine changes in:

• infection rates
• disease incidence
• hospitalizations
• complications
• deaths
• healthcare costs
• outbreaks

They may also consider:

• side effects
• cost
• accessibility
• storage requirements
• public acceptance
• duration of protection

A strong evaluation considers both benefits and limitations.

---

Challenges in Vaccine Distribution

Developing a vaccine does not automatically mean everyone can receive it.

Practical challenges include:

• manufacturing capacity
• transportation
• refrigeration
• trained healthcare workers
• cost
• supply chains
• access to clinics

Some vaccines require a cold chain—continuous temperature-controlled storage and transport.

This can be especially challenging in remote locations.

---

Vaccine Equity

Access to vaccines can vary between:

• countries
• regions
• income groups
• urban and rural communities

This raises an important public-health issue known as vaccine equity.

A highly effective vaccine has limited population impact if people who need it cannot access it.

Biotechnology therefore solves only part of the problem.

Society must also solve problems involving:

• manufacturing
• affordability
• distribution
• healthcare access
• communication

---

Traditional vs Modern Vaccine Technology

It can be tempting to think:

traditional = old and inferior

and:

modern = automatically better

This is incorrect.

Different technologies have different strengths.

Traditional Platforms

May have:

• decades of experience
• established manufacturing systems
• strong evidence for particular diseases

Modern Platforms

May offer:

• rapid redesign
• targeted antigen selection
• flexible manufacturing
• new ways of stimulating immunity

The best technology depends on the specific disease and evidence.

---

Worked Example 1: Immune Memory

A vaccinated person encounters a pathogen several months later.

Explain why their immune system may respond faster than during a first exposure.

Solution

Vaccination previously exposed the immune system to relevant antigenic information.

This produced an adaptive immune response and memory cells.

During later exposure:

memory cells recognize antigen

↓

rapid activation

↓

faster antibody and cellular responses

↓

pathogen controlled more effectively

---

Worked Example 2: Recombinant Vaccine

Scientists identify a viral surface protein that produces a useful immune response.

They insert genetic information for this protein into yeast.

The yeast produces large quantities of the protein.

What type of biotechnology is being used?

Answer

This is recombinant protein production.

The engineered yeast acts as a biological factory producing the antigen.

The antigen can then be purified and formulated into a vaccine.

---

Worked Example 3: Comparing Technologies

Consider two hypothetical vaccines.

Vaccine A

Contains an inactivated pathogen.

Vaccine B

Contains mRNA encoding one pathogen antigen.

How are they different?

Vaccine A

Provides pathogen material directly.

Vaccine B

Provides temporary genetic instructions that allow cells to produce an antigen.

Both aim to generate:

adaptive immune response + immune memory

but they use different methods to present antigenic information.

---

Worked Example 4: Evaluating Impact

Before a vaccination program:

10,000 cases per year

After widespread vaccination:

1,500 cases per year

Decrease:

10,000 − 1,500 = 8,500 cases

Percentage decrease:

8,500 ÷ 10,000 × 100 = 85%

This observation is consistent with a major reduction.

However, researchers would still investigate other possible influences, such as:

• changes in testing
• population changes
• other public-health measures
• changes in pathogen circulation

Good science considers alternative explanations.

---

Common Mistakes

Mistake 1: "Vaccines kill every pathogen immediately."

Vaccines mainly prepare the immune system to respond more effectively.

---

Mistake 2: "Antibiotics and vaccines do the same thing."

Vaccines generally prevent disease by preparing immunity.

Antibiotics treat susceptible bacterial infections.

---

Mistake 3: "Vaccination always means you cannot become infected."

Protection depends on the vaccine and disease.

Some vaccines primarily reduce the risk of severe disease rather than completely preventing every infection.

---

Mistake 4: "mRNA vaccines change a person's DNA."

Vaccine mRNA provides temporary instructions used by ribosomes and is subsequently degraded. It does not need to alter DNA to work.

---

Mistake 5: "mRNA remains permanently inside cells."

mRNA is naturally broken down.

The longer-lasting effect is the immune memory, not permanent persistence of vaccine mRNA.

---

Mistake 6: "Modern vaccines contain the disease."

Different vaccine technologies contain different materials.

For example, an mRNA vaccine contains genetic instructions rather than the complete disease-causing pathogen.

---

Mistake 7: "If something happens after vaccination, the vaccine caused it."

Events occurring after vaccination are investigated, but timing alone does not establish causation.

---

Mistake 8: "New vaccine technology means scientists can skip testing."

Rapid design and manufacturing technologies can shorten parts of development, but appropriate testing and regulatory evaluation remain necessary.

---

Mistake 9: "All vaccines work in exactly the same way."

Different vaccines use different technologies and can stimulate different patterns of immune response.

---

Mistake 10: "Vaccines only benefit the person receiving them."

For vaccines that reduce transmission, vaccination can also reduce opportunities for pathogens to spread through a population.

---

Check Your Understanding

1. Recall

Define:

• pathogen
• antigen
• antibody
• vaccine
• immune memory

2. Immune Response

Explain how vaccination can produce a faster response when a person later encounters the pathogen.

Use:

• antigen
• B cell
• antibody
• memory cell

in your answer.

3. Compare

Explain the difference between:

live attenuated

and

inactivated

vaccines.

4. Biotechnology

Explain how genetically engineered microorganisms can be used to manufacture an antigen for a recombinant vaccine.

5. mRNA

Describe how an mRNA vaccine results in production of an antigen.

Your answer should include:

mRNA → ribosome → antigen → immune response

6. Outbreaks

Identify four ways biotechnology can help scientists during an infectious-disease outbreak.

7. Genomic Surveillance

Explain why scientists sequence pathogen genomes during an outbreak.

8. Public Health

Explain how vaccination can provide benefits at both:

• the individual level
• the population level

9. Evaluation

A new vaccine greatly reduces severe disease but only moderately reduces infection.

A student says:

"The vaccine doesn't work because vaccinated people can still become infected."

Evaluate this statement.

10. Challenge

Two vaccines protect against the same disease.

Vaccine A

• 95% reduction in severe disease
• requires extremely cold storage
• relatively expensive to distribute

Vaccine B

• 90% reduction in severe disease
• can be stored in a normal refrigerator
• inexpensive to distribute

Explain why public-health officials would need more information before deciding how the vaccines should be used.

Consider:

• effectiveness against different outcomes
• safety
• duration of protection
• population
• cost
• storage
• distribution
• accessibility

---

Key Terms

• Vaccine – preparation designed to produce protective immunity against a particular disease
• Pathogen – disease-causing biological agent
• Antigen – molecule or structure recognized by the immune system
• Antibody – protein that binds specifically to a particular molecular target
• B cell – lymphocyte involved in antibody-mediated immunity
• T cell – lymphocyte involved in coordinating immune responses or recognizing infected cells
• Memory cell – long-lived immune cell capable of responding rapidly to later exposure
• Adaptive immunity – targeted immune response that can develop immunological memory
• Live attenuated vaccine – vaccine containing a weakened pathogen
• Inactivated vaccine – vaccine containing pathogen material unable to replicate
• Toxoid vaccine – vaccine using an inactivated bacterial toxin
• Subunit vaccine – vaccine containing selected pathogen components
• Recombinant vaccine – vaccine containing components produced using recombinant biotechnology
• Virus-like particle (VLP) – structure resembling a virus but lacking the complete genetic system required for normal viral replication
• Viral vector – modified virus used to deliver genetic information
• mRNA vaccine – vaccine using messenger RNA encoding an antigen
• Lipid nanoparticle – lipid-based structure used to deliver molecules such as mRNA into cells
• Genomic surveillance – monitoring pathogen genetic variation through sequencing
• Vaccine effectiveness – measure of how well vaccination reduces a specified health outcome under real-world conditions
• Population immunity – population-level reduction in transmission resulting from sufficient immunity
• Pharmacovigilance – continued monitoring of the safety of medical products
• Cold chain – temperature-controlled storage and transportation system
• Vaccine equity – fair access to vaccination across populations

---

Key Takeaways

• Vaccines prepare the adaptive immune system to respond to particular pathogens or antigens.
• Vaccination can produce memory B cells and T cells, allowing faster responses during later exposure.
• Vaccines can reduce infection, disease, severe disease, complications, hospitalization, or death, depending on the vaccine and pathogen.
• Traditional vaccine technologies include live attenuated, inactivated, and toxoid vaccines.
• Modern biotechnology has expanded vaccine technologies to include recombinant proteins, virus-like particles, viral vectors, mRNA, and DNA approaches.
• Genetically engineered cells can act as biological factories that manufacture vaccine antigens.
• The recombinant hepatitis B vaccine is an important example of biotechnology being used to produce a vaccine antigen.
• mRNA vaccines provide temporary genetic instructions that allow cells to produce an antigen.
• Vaccine mRNA is eventually degraded; immune memory can persist after the mRNA is gone.
• Genome sequencing allows scientists to identify pathogens and monitor their evolution.
• Biotechnology can accelerate parts of vaccine design during outbreaks, but appropriate testing, quality control, and regulatory evaluation remain necessary.
• Vaccination can benefit individuals and, when it reduces transmission, contribute to population-level protection.
• Vaccination contributed to the global eradication of smallpox.
• Vaccine safety is evaluated both before introduction and through continued monitoring afterward.
• An event occurring after vaccination does not automatically demonstrate that vaccination caused it.
• The impact of vaccination depends not only on biology but also on manufacturing, cost, storage, distribution, access, and public-health systems.
• Different vaccine technologies have different advantages and limitations; there is no single platform that is best for every disease.
• Biotechnology has transformed vaccine science by giving researchers more ways to identify pathogens, design antigens, manufacture vaccines, monitor outbreaks, and respond to emerging infectious diseases.